Ipilimumab injection
Products billed under this code include Yervoy.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Yervoy.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Yervoy | E.R. Squibb & Sons, L.L.C. | 00003-2327-11 | 50 | $9,521.65 |
| Yervoy | E.R. Squibb & Sons, L.L.C. | 00003-2328-22 | 200 | $38,086.60 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $190.433 | +$0.001 | 1 MG | Ipilimumab injection | v1, posted September 17, 2026 |
| 3Q26 | $190.432 | +$3.266 | 1 MG | Ipilimumab injection | v1, posted September 15, 2026 |
| 2Q26 | $187.166 | +$0.252 | 1 MG | Ipilimumab injection | v1, posted September 15, 2026 |
| 1Q26 | $186.914 | +$3.435 | 1 MG | Ipilimumab injection | v1, posted September 15, 2026 |
| 4Q25 | $183.479 | +$0.065 | 1 MG | Ipilimumab injection | v1, posted September 8, 2026 |
| 3Q25 | $183.414 | +$3.199 | 1 MG | Ipilimumab injection | v1, posted March 10, 2026 |
| 2Q25 | $180.215 | +$0.164 | 1 MG | Ipilimumab injection | v1, posted March 10, 2026 |
| 1Q25 | $180.051 | +$3.167 | 1 MG | Ipilimumab injection | v1, posted December 19, 2025 |
| 4Q24 | $176.884 | +$0.10 | 1 MG | Ipilimumab injection | v1, posted June 11, 2025 |
| 3Q24 | $176.784 | +$4.075 | 1 MG | Ipilimumab injection | v1, posted June 11, 2025 |
| 2Q24 | $172.709 | +$0.29 | 1 MG | Ipilimumab injection | v1, posted March 11, 2025 |
| 1Q24 | $172.419 | +$3.859 | 1 MG | Ipilimumab injection | v1, posted December 19, 2024 |
| 4Q23 | $168.56 | +$0.627 | 1 MG | Ipilimumab injection | v1, posted October 10, 2024 |
| 3Q23 | $167.933 | +$2.48 | 1 MG | Ipilimumab injection | v1, posted June 5, 2024 |
| 2Q23 | $165.453 | −$0.316 | 1 MG | Ipilimumab injection | v1, posted February 23, 2024 |
| 1Q23 | $165.769 | +$2.665 | 1 MG | Ipilimumab injection | v1, posted December 6, 2023 |
| 4Q22 | $163.104 | −$0.555 | 1 MG | Ipilimumab injection | v1, posted June 22, 2023 |
| 3Q22 | $163.659 | +$2.826 | 1 MG | Ipilimumab injection | v1, posted June 9, 2023 |
| 2Q22 | $160.833 | +$0.13 | 1 MG | Ipilimumab injection | v1, posted December 14, 2022 |
| 1Q22 | $160.703 | +$2.055 | 1 MG | Ipilimumab injection | v1, posted June 8, 2022 |
| 4Q21 | $158.648 | −$0.193 | 1 MG | Ipilimumab injection | v1, posted June 2, 2022 |
| 3Q21 | $158.841 | +$2.121 | 1 MG | Ipilimumab injection | v1, posted June 2, 2022 |
| 2Q21 | $156.72 | −$0.505 | 1 MG | Ipilimumab injection | v1, posted March 1, 2022 |
| 1Q21 | $157.225 | – | 1 MG | Ipilimumab injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.